Notice NOT-DK-24-029 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-045 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-270 from the NIH Guide for Grants and Contracts. There is increasing evidence that exposures from the external environment are important factors in overall human health in a variety of diseases and disorders including Alzheimer's Disease-Related Dementia (ADRD). The NIH supports research on environmental risk factors (ERFs) for ADRD. This Notice of Funding Opportunity (NOFO) will support research projects that takethis research further by determining how exogenous ERFs affect ADRD disease mechanisms and phenotypic outcomes through innervated human surfaces. Exogenous ERFs include toxins and toxic chemicals, other pathogens, and other environmental exposures that reach innervated human surfaces. These surfaces include the gut, mouth, throat, lungs, nasal passages, skin and other surfaces that interface with the outside world. The scope of this NOFO includes mechanistic research relevant to ADRD to determine the effect(s) of exogenous ERFs at nervous system biological interfaces. Human studies (No Clinical Trials Allowed) to identify exogenous ERFs at these biological interfaces are also allowed if the mechanistic influence of these exposures is also included in the research plan. This initiative will require team science between neuroscientists that have deep expertise in ADRD research with experts in environmental science with knowledge of toxicity to the nervous system.

Notice NOT-AG-24-060 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-262 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit Small Business Technology Transfer (STTR) grant applications from small businesses to develop innovative solutions for commercialization that would enable population screening for common, actionable genomic conditions in a primary care setting.

Funding Opportunity RFA-HD-25-003 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the Pediatric HIV/AIDS Cohort Study (PHACS) as a transformative and agile program addressingthe developmental and clinical course of persons living with HIV, and vertically acquired HIV, with an emphasis on youth through reproductive age.

Notice NOT-NS-24-015 from the NIH Guide for Grants and Contracts

Notice NOT-HL-24-022 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-25-018 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-25-017: Type 1 Diabetes in Acute Pancreatitis Consortium Clinical Centers (T1DAPC-CC) (U01). The applicant for the Data Coordinating Center (DCC) must have experience serving as the DCC for studies on complex, clinical conditions, like the occurrence of diabetes mellitus (DM) after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and the DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after acute pancreatitis. The Consortia will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have recovered from one or more episodes of acute pancreatitis due to various identifiable etiologies. The DCC will provide overall project coordination, administration, quality control, data management and biostatistical support.

Funding Opportunity RFA-DK-25-017 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), that occurs after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes that occurs during or after one or more episodes of acute pancreatitis. The teams will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have impaired glucose tolerance or diabetes mellitus after one or more episodes of acute pancreatitis due to various identifiable etiologies. Applications for the Data Coordinating Center (DCC) are submitted in response to a separate NOFO: RFA-DK-25-018: Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC) (U01).

Funding Opportunity PAR-24-263 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit Small Business Innovation Research (SBIR) grant applications from small businesses to develop innovative solutions for commercialization that would enable population screening for common, actionable genomic conditions in a primary care setting.

Funding Opportunity RFA-DA-26-008 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address HIV-substance use disorders (SUD) comorbidity. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Funding Opportunity RFA-DA-26-007 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address HIV-substance use disorders (SUD) comorbidity. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Notice NOT-CA-24-095 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-093 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-25-012 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO) as a request for applications (RFA), the National Cancer Institute (NCI) intends to support pilot/exploratory research that expands the current understanding of the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer; assesses the impact of these two converging stigmas on cancer outcomes among PWH with cancer; leverages stigma reduction interventions at multiple levels to intervene on modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer; and promotes research in domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated.

Funding Opportunity RFA-CA-25-011 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO) as a request for applications (RFA), the National Cancer Institute (NCI) intends to support research that expands the current understanding of the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer; assesses the impact of these two converging stigmas on cancer outcomes among PWH with cancer; leverages stigma reduction interventions at multiple levels to intervene on modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer; and promotes research in domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated.

Notice NOT-HL-24-026 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-26-001 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses.